{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.5","upperLimit":"100","value":"98.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Estimated along with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"through out study treatment and up to 30 days after completion of study treatment, up to 119 months","title":"Best Response Rate (Stringent Complete Response [sCR]/Near Complete Response [nCR]/Very Good Partial Response [VGPR]/Partial Response [PR])","type":"SECONDARY","unitOfMeasure":"percentage of participants"}